Oral Insulin diabetic dogs

Journal of Endocrinology (1991) 131, 267-278 DOI: 10.1677/joe.0.1310267 © 1991 Society for Endocrinology Oral insulin in diabetic dogs M. Saffran, J. B. Field, J. Peña, R. H. Jones and Y. Okuda Bovine crystalline insulin, mixed with an absorption enhancer, was loaded by hand into gelatin capsules, which were then coated with an azopolymer designed to deliver the insulin in the upper colon. In 34 experiments with 14 pancreatectomized mongrel dogs of both sexes, the coated capsules were administered orally after a pre-dose period of 1 h. The dogs had cannulae in the portal vein, hepatic vein and femoral artery and Doppler flow probes on the portal vein and hepatic artery. Insulin and food were withdrawn the day before an experiment. Responses measured were plasma glucose, plasma insulin, hepatic glucose production rate, hepatic plasma flow rate and plasma glucagon-like immunoactivity (GLI). Control experiments, with capsules without insulin, produced small changes from 'pre-dose' values. Insulin-containing capsules, without the azopolymer coating, resulted in some early changes consistent with upper gastrointestinal absorption. Single oral doses (66 to 400 nmol/kg) of insulin in completely coated capsules produced peaks of portal plasma insulin and transient decreases in plasma glucose, hepatic glucose production, hepatic plasma flow and plasma GLI. The changes usually began 1·5–2 h after administration of a single dose, and lasted for up to 3 h, but were not significantly related to the dose of insulin. Multiple oral doses of insulin, given at 1·5-h intervals, resulted in multiple peaks of plasma insulin, a continuing dose-dependent fall in plasma glucose to near-euglycaemia with the highest dose, and profound decreases in hepatic glucose production and plasma GLI. These data demonstrate that insulin absorbed from the gastrointestinal tract causes changes in glucose metabolism in the diabetic dog that are consistent with the action of insulin primarily on the liver and that repeated oral doses are necessary to correct the hyperglycaemia. Journal of Endocrinology (1991) 131, 267–278 This article has been cited by other articles: HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS QUICK SEARCH: [advanced] Go Author: Keyword(s): Year: Vol: Page: Institution: Universite de Montreal | Sign In via User Name/Password This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saffran, M. Articles by Okuda, Y. Search for Related Content PubMed PubMed Citation Articles by Saffran, M. Articles by Okuda, Y.

Upload
salah-el-moustaghfir
Category

Documents
view
218
download
0

Embed Size (px):

description

Transcript of Oral Insulin diabetic dogs

Oral insulin in diabetic dogs M. Saffran, J. B. Field, J. Peña, R. H. Jones and Y. Okuda

Bovine crystalline insulin, mixed with an absorption enhancer, was loaded by hand into gelatin capsules, which were then coated with an azopolymer designed to deliver the insulin in the upper colon. In 34 experiments with 14 pancreatectomized mongrel dogs of both sexes, the coated capsules were administered orally after a pre-dose period of 1 h. The dogs had cannulae in the portal vein, hepatic vein and femoral artery and Doppler flow probes on the portal vein and hepatic artery. Insulin and food were withdrawn the day before an experiment. Responses measured were plasma glucose, plasma insulin, hepatic glucose production rate, hepatic plasma flow rate and plasma glucagon-like immunoactivity (GLI). Control experiments, with capsules without insulin, produced small changes from 'pre-dose' values. Insulin-containing capsules, without the azopolymer coating, resulted in some early changes consistent with upper gastrointestinal absorption. Single oral doses (66 to 400 nmol/kg) of insulin in completely coated capsules produced peaks of portal plasma insulin and transient decreases in plasma glucose, hepatic glucose production, hepatic plasma flow and plasma GLI. The changes usually began 1·5–2 h after administration of a single dose, and lasted for up to 3 h, but were not significantly related to the dose of insulin. Multiple oral doses of insulin, given at 1·5-h intervals, resulted in multiple peaks of plasma insulin, a continuing dose-dependent fall in plasma glucose to near-euglycaemia with the highest dose, and profound decreases in hepatic glucose production and plasma GLI. These data demonstrate that insulin absorbed from the gastrointestinal tract causes changes in glucose metabolism in the diabetic dog that are consistent with the action of insulin primarily on the liver and that repeated oral doses are necessary to correct the hyperglycaemia.

Journal of Endocrinology (1991) 131, 267–278

This article has been cited by other articles:

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

QUICK SEARCH: [advanced]

GoAuthor: Keyword(s):

Year: Vol: Page: Institution: Universite de Montreal | Sign In via User Name/Password

This Article

Full Text (PDF)

Alert me when this article is cited

Alert me if a correction is posted

Services

Similar articles in PubMed

Alert me to new issues of the journal

Download to citation manager

Citing Articles

Citing Articles via HighWire

Citing Articles via Google Scholar

Google Scholar

Articles by Saffran, M.

Articles by Okuda, Y.

Search for Related Content

PubMed

PubMed Citation

Articles by Saffran, M.

Articles by Okuda, Y.

A. Iaconelli, L. Fiorentini, S. Bruschi, F. Rossi, G. Mingrone, and G. Piva Absence of Allergic Reactions to Egg White Lysozyme Additive in Grana Padano Cheese J. Am. Coll. Nutr., April 1, 2008; 27(2): 326 - 331. [Abstract] [Full Text] [PDF]

M. Nishikawa, S. Hasegawa, F. Yamashita, Y. Takakura, and M. Hashida Electrical charge on protein regulates its absorption from the rat small intestine Am J Physiol Gastrointest Liver Physiol, April 1, 2002; 282(4): G711 - G719. [Abstract] [Full Text] [PDF]

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS